Fintel reports that on July 8, 2025, Scotiabank downgraded their outlook for Sage Therapeutics (NasdaqGM:SAGE) from Sector ...

A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have lost about 11.1% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Sage Therapeutics, Inc. SAGE is focused on developing life-changing brain health medicines. In July, Sage Therapeutics and partner Biogen BIIB announced top-line data from the phase II KINETIC 2 ...

Sage Therapeutics (NASDAQ:SAGE) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Sage ...

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

Sage Therapeutics Inc.'s stock (SAGE) fell 2.4% Wednesday, headed for a fresh all-time low after the company said it would cease developing a treatment for cognitive impairment associated with ...

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by late August.

Zinger Key Points. Sage Therapeutics to lay off 165+ employees, roughly 33% of workforce, by Q4 2024. Company halts SAGE-324 and dalzanemdor trials after disappointing results.

Sage is lopping off one-third of its workforce after one of its experimental drugs failed to prove effective as a treatment for Parkinson's and Alzheimer's diseases. Anne Marie Cook, general ...